Bright Minds Biosciences Inc. SEC filings DRUG
Bright Minds Biosciences Inc. has 180 filings in SEC EDGAR's recent list, going back to Oct 6, 2020. Its latest annual report, Form 40-F, was filed on Dec 23, 2025 for the period ended Sep 30, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026. The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 12, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 2, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 12, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 30, 2026 | — |
| 4 | Insider transaction | Apr 30, 2026 | Apr 28, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 6, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 13, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 12, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 8, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 7, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 10, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 7, 2025 | — |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| 4 | Insider transaction | Nov 6, 2024 | Nov 4, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 6, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 5, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 5, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 25, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 23, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 23, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 22, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 22, 2024 | — |
| 4 | Insider transaction | Oct 17, 2024 | Oct 15, 2024 |
| 3 | Initial insider ownership | Oct 17, 2024 | Oct 15, 2024 |
| SC 13G | Ownership over 5% (passive) | Oct 16, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 26, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 26, 2024 | — |
| SC 13D | Ownership over 5% (active) | Jan 18, 2024 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRUG (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1827401
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.